The creation of a global leader in Biosimilars

Alvotech was founded in 2013 by the Chairman and CEO, Robert Wessman. His initial strategy was to invest in the development and manufacture of a portfolio of biosimilar monoclonal antibodies and to build a state-of-the-art manufacturing facility in Reykjavik Iceland

Since then, the investment commitment has increased to more than $600 million and Alvotech has established itself as a key player and up-and-coming powerhouse in the biosimilar space.

Our milestones


  • Founding of Alvotech and start of development for the first two biosimilars
  • Breaking ground on state-of-the-art, 13,278 squaremeters single use biomanufacturing facility in Reykjavik, Iceland
  • Strategic investments to increase R&D capabilities


  • Development of next two product candidates initiated, bringing pipeline to four biosimilars
  • Partnership agreement with a global pharma company signed


  • Continuing product development and facility establishment build-up of capacity and staff


  • Next two biosimilars selected to bring pipeline to six assets
  • Acquisition of development arm of Baliopharm GmbH to further strengthen our R&D platform
  • Manufacturing facility undergoing first inspection
  • Inauguration of our Icelandic facility


  • One biosimilar selection to bring pipeline to seven assets
  • Acquisition of Glycothera in Hanover, Germany adding further analytical capabilities and expertise


  • Manufacturing licensure granted by the Icelandic Medicines Agency, in consultation with the Irish Health Products Regulatory Authority for our biopharmaceutical facility in Reykjavik, Iceland
  • Agreement with Changchun High & New Technology Industries Group Inc (“CCHN”) which will enable Alvotech to develop, manufacture and commercialize its biosimilar portfolio in China


  • Alvotech completes US$300 million financing deal through a private bond offering
  • Work begins on Alvotech-CCHN joint venture in China
  • Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA®
  • Alvotech and Fuji Pharma announce exclusive partnership agreement to commercialize Alvotech’s ustekinumab biosimilar (Stelara®) in Japan
  • Mark Levick appointed CEO of Alvotech
We use cookies to ensure our website works properly and to collect statistics about users in order for us to improve the website. Learn more.